{
    "Trade/Device Name(s)": [
        "Yumizen C1200 Immunoglobulin A",
        "Yumizen C1200 Immunoglobulin G",
        "Yumizen C1200 Immunoglobulin M"
    ],
    "Submitter Information": "HORIBA ABX SAS",
    "510(k) Number": "K193525",
    "Predicate Device Reference 510(k) Number(s)": [
        "K073489",
        "K073490",
        "K073487"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CZP",
        "DEW",
        "CFN"
    ],
    "Summary Letter Date": "December 17, 2019",
    "Summary Letter Received Date": "December 19, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, and E immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Immunoglobulin A (IgA)",
        "Immunoglobulin G (IgG)",
        "Immunoglobulin M (IgM)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Yumizen C1200 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetry"
    ],
    "Methodologies": [
        "Endpoint photometric immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Yumizen C1200 Immunoglobulin A, G, and M immunoturbidimetric reagents for quantitative measurement of immunoglobulins in serum and lithium heparin plasma on the Yumizen C1200 analyzer.",
    "Indications for Use Summary": "Quantitative in vitro diagnostic determination of Immunoglobulin A, G, and M in serum and lithium heparin plasma to aid in diagnosing abnormal protein metabolism and the body's resistance to infectious agents, for use on Yumizen analyzers in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}